Peter Guenter – Chief Executive Officer, Healthcare – Merck KGaA, Darmstadt, Germany | LinkedIn
CEO of Almirall, Peter Guenter, on being a successful leader - YouTube
Peter Guenter - Company
Peter Merck Fotografías e imágenes de stock - Getty Images
Peter Guenter deja Almirall y se incorpora a Merck | Cataluña
Peter Guenter - CEO, Healthcare & Executive Board Member at Merck Group | The Org
:format(jpg)/f.elconfidencial.com%2Foriginal%2F1ca%2F329%2Fed7%2F1ca329ed7dcef7626175ff052d542215.jpg "Merck asciende a Belén Garijo a CEO y ficha al primer ejecutivo de Almirall")
Merck asciende a Belén Garijo a CEO y ficha al primer ejecutivo de Almirall
Belén Garijo nombrada nueva consejera delegada mundial de la farmacéutica alemana Merck | Economía | EL PAÍS
Peter Guenter | CHEManager
EMD Serono on Twitter: "This week, we welcomed Peter Guenter, CEO of Healthcare at Merck KGaA, Darmstadt, Germany (@EMDGroup) on his 1st visit to the US since taking on this role. From
CEO-Wechsel bei Merck bis Mitte 2021
Peter Guenter, member of the Executive Board of Merck KGaA and... News Photo - Getty Images
Merck KGaA Healthcare Head Happy With Old And New Mix :: Scrip
Manuel Zafra, nuevo director general de Merck en España - El Global
El CEO de Almirall invierte 500.000 euros en acciones 10 días antes de dejar el cargo | Empresas | Cinco Días
Peter Guenter - Download gallery | Merck
Peter Guenter, CEO de Almirall, abandonará la compañía para fichar por Merck
Peter Guenter email address & phone number | Merck Kgaa, Darmstadt, Germany Chief Executive Officer, Healthcare contact information - RocketReach
El 'escáner' de la semana: del aterrizaje de Moderna en España a la salida de Peter Guenter de Almirall | PlantaDoce
Peter Guenter – Chief Executive Officer, Healthcare – Merck KGaA, Darmstadt, Germany | LinkedIn
Peter Guenter – Chief Executive Officer, Healthcare – Merck KGaA, Darmstadt, Germany | LinkedIn
Empresas|Merck elige a Belén Garijo como su CEO global
Peter Guenter (CEO Merck healthcare): 'Het farmamodel werkt wél'
After a year as Merck KGaA healthcare CEO, Guenter reflects on I-O bispecific flop, spots new multiple sclerosis strategy | Fierce Biotech
Merck leaning on new phase 3 oncology assets to weather storm in 2023 < Pharma < Article - KBR
